As measles outbreaks increase domestically & internationally, while vaccination uptake decreases in the U.S., experts discuss treatment recommendations & the immunologic consequences of measles infections in patients with rheumatic diseases.
A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
This year, Dr. Sam Shapiro underwent total hip arthroplasty. Her journey from being an athlete to suffering from arthritis and chronic joint pain was difficult. Here is her story, complete with post-op insights.
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
Matteo Piga, MD, highlighted the latest research into Behçet’s disease, including developments into the understanding of its pathophysiology and positive results for potential treatments.
In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
Ustekinumab-stba (Steqeyma) now has FDA approval for all forms and dosages of its reference product, ustekinumab (Stelara), including a subcutaneous injection to treat pediatric patients with plaque psoriasis or psoriatic arthritis.
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.